-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Blueprint Medicines announced today that the U.
AYVAKIT (avapritinib) is a kinase inhibitor that has been approved by the FDA for the treatment of adult patients with gastrointestinal stromal tumors (GIST) who carry PDGFRA exon 18 mutations, including PDGFRA D842V mutations
Mr.
Reference: [1] FDA Approves Blueprint Medicines' AYVAKIT™ (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis.
Reference: [1] FDA Approves Blueprint Medicines' AYVAKIT™ (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis.
Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options
.
If you need guidance on the treatment plan, please go to a regular hospital for treatment
.